Ascendis Pharma A/S (ASND) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Wait for pullback to $220.25. At $229.11 the A.R:R is 1.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $220.25 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Value-trap signals (3/5): Margin compression (op margin -2.5%), High leverage (D/E 16.5), Material insider selling (8 sells, 0.72% of cap).
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency;... Read more
Wait for pullback to $220.25. At $229.11 the A.R:R is 1.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $220.25 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Value-trap signals (3/5): Margin compression (op margin -2.5%), High leverage (D/E 16.5), Material insider selling (8 sells, 0.72% of cap). Chart setup: RSI 42 mid-range, Bollinger mid-band. Earnings in 0 days. Wait until post-earnings. Score 5.4/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $220.25. At $229.11 the A.R:R is 1.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $220.25 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Value-trap signals (3/5): Margin compression (op margin -2.5%), High leverage (D/E 16.5), Material insider selling (8 sells, 0.72% of cap). Chart setup: RSI 42 mid-range, Bollinger mid-band. Earnings in 0 days. Wait until post-earnings. Target $252.13 (+10.0%), stop $203.85 (−12.4%), Setup A.R:R 2.8:1. Score 5.4/10, moderate confidence.
Take-profit target: $252.13 (+14.2% upside). Target $252.13 (+10.0%), stop $203.85 (−12.4%), Setup A.R:R 2.8:1. Stop-loss: $203.85.
Value-trap signals (3/5): Margin compression (op margin -2.5%), High leverage (D/E 16.5), Material insider selling (8 sells, 0.72% of cap).
Ascendis Pharma A/S trades at a P/E of N/A (forward 24.6). TrendMatrix value score: 4.5/10. Verdict: Buy (Wait for Entry).
24 analysts cover ASND with a consensus score of 4.4/5. Average price target: $297.
What does Ascendis Pharma A/S do?Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for...
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.